BCWM
AXDX

Bartlett & Co Wealth Management’s Accelerate Diagnostics AXDX Stock Holding History

Bartlett & Co Wealth Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$1 – 1207
2025
Q2 		$1 Hold
100
– – ﹤0.01% 1243
2025
Q1 		$70 Hold
100
– – ﹤0.01% 1215
2024
Q4 		$120 Hold
100
– – ﹤0.01% 1108
2024
Q3 		$171 Hold
100
– – ﹤0.01% 1106
2024
Q2 		$117 Hold
100
– – ﹤0.01% 1120
2024
Q1 		$99 Hold
100
– – ﹤0.01% 1111
2023
Q4 		$400 Sell
100
-100
-50% -$529 ﹤0.01% 1201
2023
Q3 		$1.15K Hold
200
– – ﹤0.01% 1105
2023
Q2 		$1.62K Hold
200
– – ﹤0.01% 1080
2023
Q1 		$1.4K Hold
200
– – ﹤0.01% 999
2022
Q4 		$1.41K Hold
200
– – ﹤0.01% 1032
2022
Q3 		$3.04K Hold
200
– – ﹤0.01% 1001
2022
Q2 		$1.99K Hold
200
– – ﹤0.01% 1177
2022
Q1 		$392K Buy
+200
New +$5.7K 0.01% 317

Bartlett & Co Wealth Management's AXDX Position: Q3 2025 in Review

Bartlett & Co Wealth Management sold out of Accelerate Diagnostics (AXDX) in Q3 2025, closing a stake of 100 shares — an estimated $1 sold.

Bartlett & Co Wealth Management first reported a position in AXDX in Q1 2022 and held it in 14 quarters. The position peaked at $392K in Q1 2022. 0 funds tracked by Wall St. Rank hold AXDX as of Q3 2025.

  • Bartlett & Co Wealth Management reported no remaining Accelerate Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 100 Accelerate Diagnostics shares in Q3 2025, an estimated $1.
  • Bartlett & Co Wealth Management first reported a position in Accelerate Diagnostics in Q1 2022 and held it in 14 quarters.
  • Bartlett & Co Wealth Management's Accelerate Diagnostics position peaked at $392K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2025.

Based on Bartlett & Co Wealth Management's 13F filing for Q3 2025, filed 9 Oct 2025.